Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

152.64 2.07 −1.34%
Market cap
$17.3B
P/E
72.7×
Fwd P/E
37.5×
Dividend yield
0.23%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100

Revvity Inc. (RVTY) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Revvity Inc. (RVTY) trades at a P/E ratio of 72.7×. Over the past ten years it has ranged from 13.4× (May 2021) to 93.6× (May 2024); the current reading is higher than 93% of that period. That is above the Diagnostics & Research industry median of 35.6× and above the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 46.5× (7.90%)
FY2024 50.5× 151.53%
FY2023 20.1× (34.85%)
FY2022 30.8× 23.84%
FY2021 24.9× 12.37%
FY2020 22.1× (53.47%)
FY2019 47.6× 29.07%
FY2018 36.9× 31.72%
FY2017 28.0× 12.53%
FY2016 24.9× (12.69%)

Quarterly newest first

Period P/E ratio Change
Jun 2026 53.0× 26.39%
Mar 2026 41.9× (9.88%)
Dec 2025 46.5× 5.61%
Sep 2025 44.0× 7.47%
42 more quarters

Against its own ten years

Low 13.4× High 93.6×
Ten-year median 32.6×
Current reading's percentile 92

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on RVTY